Davide Capodanno

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4864408/publications.pdf

Version: 2024-02-01

484 papers	37,831 citations	9234 74 h-index	3714 179 g-index
497 all docs	497 docs citations	497 times ranked	25451 citing authors

#	Article	IF	Citations
1	Polymer-Free Biolimus-Eluting Stents or Polymer-Based Zotarolimus-Eluting Stents for Coronary Bifurcation Lesions. Cardiovascular Revascularization Medicine, 2022, 35, 66-73.	0.3	3
2	Efficacy and safety of dual-pathway inhibition in patients with cardiovascular disease: a meta-analysis of 49 802 patients from 7 randomized trials. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 519-528.	1.4	13
3	Oral antithrombotic therapy for the prevention of recurrent cerebrovascular events. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 383-391.	1.4	3
4	Ultrasound- Versus Fluoroscopy-Guided Femoral Access for Percutaneous Coronary Intervention of Chronic Total Occlusions: Insights From FOUND BLOOD CTO Registry. Cardiovascular Revascularization Medicine, 2022, 38, 61-67.	0.3	5
5	Bleeding avoidance strategies in percutaneous coronary intervention. Nature Reviews Cardiology, 2022, 19, 117-132.	6.1	71
6	Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 677-686.	1.4	45
7	Efficacy and Safety of Aspirin for Primary Cardiovascular Risk Prevention in Younger and Older Age: An Updated Systematic Review and Meta-analysis of 173,810 Subjects from 21 Randomized Studies. Thrombosis and Haemostasis, 2022, 122, 445-455.	1.8	14
8	Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials. European Heart Journal, 2022, 43, 959-967.	1.0	79
9	Anti-inflammatory strategies for atherosclerotic artery disease. Expert Opinion on Drug Safety, 2022, 21, 661-672.	1.0	4
10	Non-fatal MI as surrogate end point for all-cause or cardiovascular mortality. Nature Reviews Cardiology, 2022, , .	6.1	1
11	Current management and screening of peripheral and coronary artery disease in people with diabetes mellitus in Europe. The PADDIA/CADDIA survey. Diabetes Research and Clinical Practice, 2022, 184, 109214.	1.1	1
12	ABCDâ€GENE Score and Clinical Outcomes Following Percutaneous Coronary Intervention: Insights from the TAILORâ€PCI Trial. Journal of the American Heart Association, 2022, 11, e024156.	1.6	22
13	Short Duration of DAPT Versus De-Escalation After Percutaneous Coronary Intervention for AcuteÂCoronaryÂSyndromes. JACC: Cardiovascular Interventions, 2022, 15, 268-277.	1.1	62
14	European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1â€"epidemiology, pathophysiology, and diagnosis. Cardiovascular Research, 2022, 118, 1385-1412.	1.8	27
15	Sex Differences in Outcomes After Percutaneous Coronary Intervention or Coronary Artery Bypass Graft for Left Main Disease: From the DELTA Registries. Journal of the American Heart Association, 2022, 11, e022320.	1.6	5
16	Culprit Lesions Phenotypes in ST-Segment Elevation Acute CoronaryÂSyndromes. JACC: Cardiovascular Interventions, 2022, , .	1.1	0
17	P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention. Nature Reviews Cardiology, 2022, 19, 829-844.	6.1	30
18	Use of Intravascular Imaging in Patients With ST-Segment Elevation Acute Myocardial Infarction. Cardiovascular Revascularization Medicine, 2021, 30, 59-64.	0.3	19

#	Article	IF	Citations
19	Effect of postâ€procedural evidenceâ€based therapy on 2â€year prognosis after transcatheter mitral valve repair. European Journal of Heart Failure, 2021, 23, 677-679.	2.9	2
20	Unmasking psychological reasons of delay in acute coronary syndromes presentation during the COVIDâ€19 pandemic. Catheterization and Cardiovascular Interventions, 2021, 98, 407-408.	0.7	5
21	Choices in antithrombotic management for patients with atrial fibrillation undergoing percutaneous coronary intervention: questions (and answers) in chronological sequence. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 68-73.	1.4	9
22	Accuracy of the PARIS score and PCI complexity to predict ischemic events in patients treated with very thin stents in unprotected left main or coronary bifurcations. Catheterization and Cardiovascular Interventions, 2021, 97, E227-E236.	0.7	6
23	Antithrombotic therapy in patients with acute coronary syndrome complicated by cardiogenic shock or out-of-hospital cardiac arrest: a joint position paper from the European Society of Cardiology (ESC) Working Group on Thrombosis, in association with the Acute Cardiovascular Care Association (ACCA) and European Association of Percutaneous Cardiovascular Interventions (EAPCI). European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 125-140.	1.4	31
24	Non-cardiac surgery in patients with coronary artery disease: risk evaluation and periprocedural management. Nature Reviews Cardiology, 2021, 18, 37-57.	6.1	42
25	Safety and efficacy of P2Y₁₂inhibitor monotherapy in patients undergoing percutaneous coronary interventions. Expert Opinion on Drug Safety, 2021, 20, 9-21.	1.0	18
26	Coronavirus Disease 2019â€“Associated Thrombosis and Coagulopathy: Review of the Pathophysiological Characteristics and Implications for Antithrombotic Management. Journal of the American Heart Association, 2021, 10, e019650.	1.6	122
27	Suitability for elderly with heart disease of a QR code-based feedback of drug intake: Overcoming limitations of current medication adherence telemonitoring systems.. International Journal of Cardiology, 2021, 327, 209-216.	0.8	9
28	Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials. European Heart Journal, 2021, 42, 308-319.	1.0	90
29	Does the left circumflex coronary artery location impact on the success of chronic total occlusion recanalization? A single-center cohort study. Scandinavian Cardiovascular Journal, 2021, 55, 106-108.	0.4	2
30	2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal, 2021, 42, 373-498.	1.0	5,583
31	Safe femoral access for STEMI patients and mortality in the new decade: Back to the future?. Catheterization and Cardiovascular Interventions, 2021, 97, E1054-E1056.	0.7	0
32	Prevalence and morphological changes of carotid kinking and coiling in growth: an echo-color Doppler study of 2856 subjects between aged 0 to 96Âyears. International Journal of Cardiovascular Imaging, 2021, 37, 479-484.	0.7	5
33	Safety and efficacy of non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: systematic review and meta-analysis of 22 studies and 440â€‰281 patients. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, f20-f29.	1.4	45
34	An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group. EuroIntervention, 2021, 16, 1049-1069.	1.4	90
35	At the peak of COVID-19 age and disease severity but not comorbidities are predictors of mortality: COVID-19 burden in Bergamo, Italy. Panminerva Medica, 2021, 63, 51-61.	0.2	33
36	Determinants of Popularity and Natural History of Social Media Accounts in Interventional Cardiology. JACC: Cardiovascular Interventions, 2021, 14, 720-721.	1.1	4

#	Article	IF	Citations
37	Evolving Landscapes in Coronary Stents for Patients at High Bleeding Risk. Circulation: Cardiovascular Interventions, 2021, 14, e010591.	1.4	2
38	Differences in coronary artery disease and outcomes of percutaneous coronary intervention with drug-eluting stents in women and men. Expert Review of Cardiovascular Therapy, 2021, 19, 301-312.	0.6	9
39	# SoMe for # IC : Optimal use of social media in interventional cardiology. Catheterization and Cardiovascular Interventions, 2021, 98, 97-106.	0.7	5
40	Statistical methods for composite endpoints. EuroIntervention, 2021, 16, e1484-e1495.	1.4	13
41	Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Lancet, The, 2021, 397, 1470-1483.	6.3	133
42	Triple Therapy, Dual Therapy, and Modulation of Anticoagulation Intensity. JACC: Cardiovascular Interventions, 2021, 14, 781-784.	1.1	1
43	Aspirin for Primary Prevention of Cardiovascular Disease in the 21st Century: A Review of the Evidence. American Journal of Cardiology, 2021, 144, S15-S22.	0.7	16
44	Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: a Consensus Document of the ESC Working Group on Cellular Biology of the Heart and European Association of Percutaneous Cardiovascular Interventions (EAPCI). European Heart Journal, 2021, 42, 2630-2642.	1.0	69
45	Canakinumab for secondary prevention of coronary artery disease. Future Cardiology, 2021, 17, 427-442.	0.5	10
46	Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendations. Expert Review of Clinical Pharmacology, 2021, 14, 963-978.	1.3	27
47	Sex based analysis of the impact of red blood cell transfusion and vascular or bleeding complications related to TAVI â€“ The TRITAVI-Women Study. International Journal of Cardiology, 2021, 333, 69-76.	0.8	7
48	Diagnostic pathways in myocardial infarction with non-obstructive coronary artery disease (MINOCA). European Heart Journal: Acute Cardiovascular Care, 2021, 10, 813-822.	0.4	34
49	Sexâ€Based Differences in Bleeding Risk After Percutaneous Coronary Intervention and Implications for the Academic Research Consortium High Bleeding Risk Criteria. Journal of the American Heart Association, 2021, 10, e021965.	1.6	23
50	Cangrelor: Clinical Data, Contemporary Use, and Future Perspectives. Journal of the American Heart Association, 2021, 10, e022125.	1.6	31
51	Roadmap Consensus on Carotid Artery Plaque Imaging and Impact on Therapy Strategies and Guidelines: An International, Multispecialty, Expert Review and Position Statement. American Journal of Neuroradiology, 2021, 42, 1566-1575.	1.2	25
52	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal, 2021, 42, 3227-3337.	1.0	2,517
53	Antithrombotic Therapy After Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2021, 14, 1688-1703.	1.1	31
54	Another Coronary Stent for Patients at High Bleeding Risk. JACC: Cardiovascular Interventions, 2021, 14, 1884-1887.	1.1	1

#	Article	IF	Citations
55	Impact of Post-Procedural Change in Left Ventricle Systolic Function on Survival after Percutaneous Edge-to-Edge Mitral Valve Repair. Journal of Clinical Medicine, 2021, 10, 4748.	1.0	5
56	Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease. Circulation, 2021, 144, 1323-1343.	1.6	35
57	Reflections after TWILIGHT study: a new era in secondary prevention without aspirin?. European Heart Journal Supplements, 2021, 23, E45-E50.	0.0	0
58	The Role of Antiplatelet Therapy in Patients With MINOCA. Frontiers in Cardiovascular Medicine, 2021, 8, 821297.	1.1	7
59	Appraising the contemporary role of aspirin for primary and secondary prevention of atherosclerotic cardiovascular events. Expert Review of Cardiovascular Therapy, 2021, 19, 1097-1117.	0.6	4
60	Safety and efficacy of polymerâ€free biolimusâ€eluting stents versus ultrathin stents in unprotected left main or coronary bifurcation: A propensity score analysis from the RAIN and CHANCE registries. Catheterization and Cardiovascular Interventions, 2020, 95, 522-529.	0.7	3
61	2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal, 2020, 41, 407-477.	1.0	4,210
62	Percutaneous Edge-to-Edge Mitral Valve Repair with the Mitraclip System in Barlowâ€™s Disease. Structural Heart, 2020, 4, 139-142.	0.2	0
63	Impact of structural features of very thin stents implanted in unprotected left main or coronary bifurcations on clinical outcomes. Catheterization and Cardiovascular Interventions, 2020, 96, 1-9.	0.7	15
64	Left Ventricular Size Predicts Clinical Benefit After Percutaneous Mitral Valve Repair for Secondary Mitral Regurgitation: A Systematic Review and Meta-Regression Analysis. Cardiovascular Revascularization Medicine, 2020, 21, 857-864.	0.3	5
65	Pooling the Evidence at the Patient Level: End of the Bivalirudin Saga?. Thrombosis and Haemostasis, 2020, 120, 191-193.	1.8	3
66	Comparison of Self-Expanding Bioprostheses for Transcatheter Aortic Valve Replacement in Patients With Symptomatic Severe Aortic Stenosis. Circulation, 2020, 142, 2431-2442.	1.6	96
67	Validation of high bleeding risk criteria and definition as proposed by the academic research consortium for high bleeding risk. European Heart Journal, 2020, 41, 3743-3749.	1.0	89
68	Randomized trials of invasive cardiovascular interventions that include a placebo control: a systematic review and meta-analysis. European Heart Journal, 2020, 41, 2556-2569.	1.0	16
69	Outcomes of reninâ€“angiotensinâ€“aldosterone system blockers in patients with COVID-19: a systematic review and meta-analysis. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 335-337.	1.4	19
70	An updated drug profile of ticagrelor with considerations on the treatment of patients with coronary artery disease and diabetes mellitus. Expert Review of Cardiovascular Therapy, 2020, 18, 449-464.	0.6	6
71	Acute coronary syndrome with spontaneous coronary artery dissection: which therapeutic option for a different pathophysiology?. European Heart Journal Supplements, 2020, 22, L33-L37.	0.0	1
72	Antithrombotic Therapy for Atherosclerotic Cardiovascular Disease Risk Mitigation in Patients With Coronary Artery Disease and Diabetes Mellitus. Circulation, 2020, 142, 2172-2188.	1.6	26

#	Article	IF	Citations
73	Antithrombotic treatment in atrial fibrillation patients undergoing percutaneous coronary interventions: focus on stent thrombosis. Expert Review of Cardiovascular Therapy, 2020, 18, 587-600.	0.6	5
74	Stent Wars. JACC: Cardiovascular Interventions, 2020, 13, 1706-1708.	1.1	2
75	Safety and Efficacy of Double Antithrombotic Therapy With Nonâ€“Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Metaâ€Analysis. Journal of the American Heart Association, 2020, 9, e017212.	1.6	52
76	Trial Design Principles for Patients at HighÂBleeding Risk Undergoing PCI. Journal of the American College of Cardiology, 2020, 76, 1468-1483.	1.2	35
77	Early Adverse Impact of Transfusion After Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2020, 13, e009026.	1.4	17
78	Meta-analysis Comparing Outcomes of Self-Expanding Versus Balloon-Expandable Valves for Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2020, 128, 202-209.	0.7	13
79	Selatogrel, a novel P2Y₁₂ inhibitor: a review of the pharmacology and clinical development. Expert Opinion on Investigational Drugs, 2020, 29, 537-546.	1.9	25
80	Long-term monotherapy with ticagrelor after coronary stenting: the GLOBAL LEADERS study. European Heart Journal Supplements, 2020, 22, E46-E49.	0.0	0
81	Wearable cardioverter-defibrillator in patients at risk of sudden cardiac death: consensus document from Kalarus et al. contradicts current guideline recommendationsâ€”Authorsâ€™ reply. Europace, 2020, 22, 1442-1443.	0.7	0
82	Derivation, Validation, and PrognosticÂUtility of a Prediction Rule for Nonresponse to Clopidogrel. JACC: Cardiovascular Interventions, 2020, 13, 606-617.	1.1	90
83	Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. Nature Reviews Cardiology, 2020, 17, 242-257.	6.1	87
84	How to Define Durability of Transcatheter and Surgical Bioprosthetic Aortic Valves. JACC: Cardiovascular Interventions, 2020, 13, 257-260.	1.1	1
85	Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial. Clinical Research in Cardiology, 2020, 109, 930-943.	1.5	14
86	Realâ€world reasons and outcomes for 1â€month versus longer dual antiplatelet therapy strategies with a polymerâ€free BIOLIMUS A9â€coated stent. Catheterization and Cardiovascular Interventions, 2020, 96, E248-E256.	0.7	1
87	Wearable cardioverter-defibrillator to reduce the transient risk of sudden cardiac death in coronary artery disease: Authorsâ€™ reply. Europace, 2020, 22, 1600-1601.	0.7	0
88	Meta-Analysis Comparing P2Y12 Inhibitors in Acute Coronary Syndrome. American Journal of Cardiology, 2020, 125, 1815-1822.	0.7	15
89	Defibrillators for prevention from sudden cardiac death: is it that easy?â€”Authorsâ€™ reply. Europace, 2020, 22, 1298-1299.	0.7	0
90	Validation of the Academic Research Consortium High Bleeding Risk Definition in Contemporary PCI Patients. Journal of the American College of Cardiology, 2020, 75, 2711-2722.	1.2	139

#	Article	IF	Citations
91	Anticoagulation after Transcatheter Aortic Valve Implantation: Current Status. Interventional Cardiology Review, 2020, 15, e02.	0.7	24
92	Prevention of contrast-induced acute kidney injury in patients undergoing percutaneous coronary intervention. Kardiologia Polska, 2020, 78, 967-973.	0.3	11
93	Defining device success for percutaneous coronary intervention trials: a position statement from the European Association of Percutaneous Cardiovascular Interventions of the European Society of Cardiology. EuroIntervention, 2020, 15, 1190-1198.	1.4	17
94	Mechanisms of ST-segment elevation myocardial infarction in patients with atrial fibrillation, prior stenting and long-standing chronic coronary syndrome. Cardiology Journal, 2020, 27, 8-15.	0.5	5
95	When Less Becomes More: Insights on the Pharmacodynamic Effects of Aspirin Withdrawal in Patients With Potent Platelet P2Y 12 Inhibition Induced by Ticagrelor. Journal of the American Heart Association, 2020, 9, e019432.	1.6	4
96	2018 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal, 2019, 40, 87-165.	1.0	4,537
97	2018 ESC/EACTS Guidelines on myocardial revascularization. European Journal of Cardio-thoracic Surgery, 2019, 55, 4-90.	0.6	402
98	2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm So. Europace, 2019, 21, 192-193.	0.7	209
99	Aspirin for the primary prevention of cardiovascular disease: latest evidence. Expert Review of Cardiovascular Therapy, 2019, 17, 633-643.	0.6	20
100	Cardiac arrhythmias in the emergency settings of acute coronary syndrome and revascularization: an European Heart Rhythm Association (EHRA) consensus document, endorsed by the European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Acute Cardiovascular Care Association (ACCA). Europace, 2019, 21, 1603-1604.	0.7	61
101	Stroke After Coronary Artery Bypass Grafting and Percutaneous Coronary Intervention: Incidence, Pathogenesis, and Outcomes. Journal of the American Heart Association, 2019, 8, e013032.	1.6	45
102	Management of Antithrombotic Therapy in Atrial Fibrillation Patients UndergoingÂPCI. Journal of the American College of Cardiology, 2019, 74, 83-99.	1.2	126
103	Bleeding after antiplatelet therapy for the treatment of acute coronary syndromes: a review of the evidence and evolving paradigms. Expert Opinion on Drug Safety, 2019, 18, 1171-1189.	1.0	23
104	Thrombotic Versus Bleeding Risk After Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2019, 74, 2088-2101.	1.2	57
105	Dual antithrombotic therapy for atrial fibrillation and PCI. Lancet, The, 2019, 394, 1300-1302.	6.3	10
106	Five-year clinical outcomes after percutaneous edge-to-edge mitral valve repair: Insights from the multicenter GRASP-IT registry. American Heart Journal, 2019, 217, 32-41.	1.2	50
107	Stroke After Transcatheter Aortic ValveÂReplacement. JACC: Cardiovascular Interventions, 2019, 12, 1590-1593.	1.1	10
108	Durability of Transcatheter and SurgicalÂBioprosthetic Aortic Valves in Patients at Lower Surgical Risk. Journal of the American College of Cardiology, 2019, 73, 546-553.	1.2	252

#	Article	IF	Citations
109	Antithrombotic pharmacotherapy after transcatheter aortic valve implantation: an update. Expert Review of Cardiovascular Therapy, 2019, 17, 479-496.	0.6	9
110	Optical coherence tomography evaluation of the absorb bioresorbable scaffold performance for overlap versus non-overlap segments in patients with coronary chronic total occlusion: insight from the GHOST-CTO registry. International Journal of Cardiovascular Imaging, 2019, 35, 1767-1776.	0.7	5
111	Clinical use of intracoronary imaging. Part 2: acute coronary syndromes, ambiguous coronary angiography findings, and guiding interventional decision-making: an expert consensus document of the European Association of Percutaneous Cardiovascular Interventions. European Heart Journal, 2019, 40, 2566-2584.	1.0	189
112	Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. European Heart Journal, 2019, 40, 2632-2653.	1.0	335
113	Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. Circulation, 2019, 140, 240-261.	1.6	428
114	Switching between P2Y12 inhibitors: Rationale, methods, and expected consequences. Vascular Pharmacology, 2019, 116, 4-7.	1.0	4
115	Daily risk of adverse outcomes in patients undergoing complex lesions revascularization: A subgroup analysis from the RAIN-CARDIOGROUP VII study (veRy thin stents for patients with left mAIn or) Tj ETQq1 1 0.784314 rgBT /Overlock 1	1.4	13
116	Bioabsorbable stents: only bad news?. European Heart Journal Supplements, 2019, 21, B28-B30.	0.0	13
117	Pre-Treatment With Oral P2Y12 Inhibitors in Acute Coronary Syndromes Without ST-Segment Elevation. Journal of the American College of Cardiology, 2019, 73, 915-918.	1.2	11
118	Impact of Final Kissing Balloon and of Imaging on Patients Treated on Unprotected Left Main Coronary Artery With Thin-Strut Stents (From the RAIN-CARDIOGROUP VII Study). American Journal of Cardiology, 2019, 123, 1610-1619.	0.7	20
119	Evolving paradigms in antithrombotic therapy for anticoagulated patients undergoing coronary stenting. Therapeutic Advances in Cardiovascular Disease, 2019, 13, 175394471989168.	1.0	6
120	Intravenous antiplatelet therapies (glycoprotein IIb/IIIa receptor inhibitors and cangrelor) in percutaneous coronary intervention: from pharmacology to indications for clinical use. Therapeutic Advances in Cardiovascular Disease, 2019, 13, 175394471989327.	1.0	47
121	Drug-eluting stents are not alike: does it matter?. European Heart Journal Quality of Care & Clinical Outcomes, 2019, 5, 85-87.	1.8	4
122	New-generation drug-eluting stents for left main coronary artery disease according to the EXCEL trial enrollment criteria: Insights from the all-comers, international, multicenter DELTA-2 registry. International Journal of Cardiology, 2019, 280, 30-37.	0.8	4
123	The Conundrum Surrounding Racial Differences on Ischaemic and Bleeding Risk with Dual Anti-Platelet Therapy. Thrombosis and Haemostasis, 2019, 119, 009-013.	1.8	9
124	Tailoring Antiplatelet Therapy in Patients Undergoing Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2019, 12, 33-37.	1.1	11
125	European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism. European Heart Journal, 2019, 40, 3182-3195.	1.0	240
126	Management of left main disease: an update. European Heart Journal, 2019, 40, 1454-1466.	1.0	28

#	Article	IF	Citations
127	Progress with drug-eluting stents â€“ are we done?. EuroIntervention, 2019, 14, 1623-1625.	1.4	1
128	Durability of transcatheter bioprosthetic aortic valves: the story so far. EuroIntervention, 2019, 15, 846-849.	1.4	8
129	Dual antiplatelet therapy after percutaneous coronary intervention: entering the final chapter?. EuroIntervention, 2019, 15, e475-e478.	1.4	5
130	Statistical primer: methodology and reporting of meta-analysesâ€. European Journal of Cardio-thoracic Surgery, 2018, 53, 708-713.	0.6	18
131	A Multidisciplinary Approach on theÂPerioperative Antithrombotic ManagementÂof Patients With CoronaryÂStents Undergoing Surgery. JACC: Cardiovascular Interventions, 2018, 11, 417-434.	1.1	81
132	Feasibility and Outcomes of Repeat Percutaneous Edge-to-Edge Mitral Valve Repair Procedures in Patients at High Risk forÂSurgery. JACC: Cardiovascular Interventions, 2018, 11, 818-820.	1.1	1
133	Early P2Y12 Inhibitors Escalation in Primary PCI Patients: Insights from the RENOVAMI Registry. Thrombosis and Haemostasis, 2018, 118, 852-863.	1.8	0
134	Transcatheter Therapy for Mitral Regurgitation: A Review of the Literature. , 2018, , 223-236.		0
135	Transcatheter Therapy for Aortic Stenosis: A Review of the Literature. , 2018, , 501-520.		0
136	Incidence, Timing, Causes and Predictors of Early and Late Re-Hospitalization in Patients Who Underwent Percutaneous Mitral Valve Repair With the MitraClip System. American Journal of Cardiology, 2018, 121, 1253-1259.	0.7	15
137	Early and Mid-Term Outcomes of Transcatheter Aortic Valve Replacement Using the New Generation Self-Expanding Corevalve Evolut R Device. Structural Heart, 2018, 2, 229-234.	0.2	1
138	Angiographic or Functional Success?. JACC: Cardiovascular Interventions, 2018, 11, 246-248.	1.1	0
139	Canakinumab for secondary prevention of atherosclerotic disease. Expert Opinion on Biological Therapy, 2018, 18, 215-220.	1.4	14
140	Decision Analytic Markov Model Weighting Expected Benefits and Current Limitations of First-Generation Bioresorbable Vascular Scaffolds. Circulation: Cardiovascular Interventions, 2018, 11, e005768.	1.4	10
141	The year in cardiology 2017: coronary interventions. European Heart Journal, 2018, 39, 914-924.	1.0	1
142	Current Use of Intracoronary Imaging in Interventional Practiceã€€â€• Results of a European Association of Percutaneous Cardiovascular Interventions (EAPCI) and Japanese Association of Cardiovascular Interventions and Therapeutics (CVIT) Clinical Practice Survey â€•. Circulation Journal, 2018, 82, 1360-1368.	0.7	31
143	Triple antithrombotic therapy after ACS and PCI in patients on chronic oral anticoagulation: update. Heart, 2018, 104, 1976-1983.	1.2	7
144	High on-treatment platelet reactivity and outcome in elderly with non ST-segment elevation acute coronary syndrome - Insight from the GEPRESS study. International Journal of Cardiology, 2018, 259, 20-25.	0.8	18

#	Article	IF	Citations
145	Left main coronary artery disease: pathophysiology, diagnosis, and treatment. Nature Reviews Cardiology, 2018, 15, 321-331.	6.1	73
146	Report of an ESC-EAPCI Task Force on the evaluation and use of bioresorbable scaffolds for percutaneous coronary intervention: executive summary. European Heart Journal, 2018, 39, 1591-1601.	1.0	45
147	Clinical outcomes of patients with diabetes mellitus treated with Absorb bioresorbable vascular scaffolds: a subanalysis of the <scp>E</scp>uropean <scp>M</scp>ulticentre <scp>GHOST</scp>â€<scp>EU</scp><scp>R</scp>egistry. Catheterization and Cardiovascular Interventions, 2018, 91, 444-453.	0.7	8
148	Vascular response and healing profile of everolimus-eluting bioresorbable vascular scaffolds for percutaneous treatment of chronic total coronary occlusions: A one-year optical coherence tomography analysis from the GHOST-CTO registry. International Journal of Cardiology, 2018, 253, 45-49.	0.8	7
149	Longâ€term clinical and echocardiographic outcomes of Mitraclip therapy in patients nonresponders to cardiac resynchronization. PACE - Pacing and Clinical Electrophysiology, 2018, 41, 65-72.	0.5	9
150	ACC/AHA Versus ESC Guidelines on DualÂAntiplatelet Therapy. Journal of the American College of Cardiology, 2018, 72, 2915-2931.	1.2	273
151	Gender differences on benefits and risks associated with oral antithrombotic medications for coronary artery disease. Expert Opinion on Drug Safety, 2018, 17, 1041-1052.	1.0	20
152	Platelet Function Testing after Transcatheter Aortic Valve Implantation. Thrombosis and Haemostasis, 2018, 118, 1681-1685.	1.8	8
153	Lipid Plaque Modification DuringÂResorption of Absorb Bioresorbable Scaffold. JACC: Cardiovascular Interventions, 2018, 11, 2123-2124.	1.1	3
154	CSL112, a reconstituted, infusible, plasma-derived apolipoprotein A-I: safety and tolerability profiles and implications for management in patients with myocardial infarction. Expert Opinion on Investigational Drugs, 2018, 27, 997-1005.	1.9	18
155	Incidence of Longâ€Term Structural Valve Dysfunction and Bioprosthetic Valve Failure After Transcatheter Aortic Valve Replacement. Journal of the American Heart Association, 2018, 7, e008440.	1.6	80
156	Clinical use of intracoronary imaging. Part 1: guidance and optimization of coronary interventions. An expert consensus document of the European Association of Percutaneous Cardiovascular Interventions. European Heart Journal, 2018, 39, 3281-3300.	1.0	431
157	Risk Stratification for Bleeding in the Elderly with Acute Coronary Syndrome: Not So Simple. Thrombosis and Haemostasis, 2018, 118, 949-952.	1.8	18
158	Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. Nature Reviews Cardiology, 2018, 15, 480-496.	6.1	180
159	Aspirin for primary prevention of cardiovascular disease. Lancet, The, 2018, 392, 988-990.	6.3	12
160	Bioresorbable Scaffolds in Coronary Intervention: Unmet Needs and Evolution. Korean Circulation Journal, 2018, 48, 24.	0.7	16
161	Transcatheter or surgical treatment of severe aortic stenosis and coronary artery disease: A comparative analysis from the Italian OBSERVANT study. International Journal of Cardiology, 2018, 270, 102-106.	0.8	32
162	Restenosis patterns after bioresorbable vascular scaffold implantation: Angiographic substudy of the <scp>GHOST</scp>â€<scp>EU</scp> registry. Catheterization and Cardiovascular Interventions, 2018, 92, 276-282.	0.7	4

#	Article	IF	Citations
163	Risk Stratification in Patients with Coronary Artery Disease: a Practical Walkthrough in the Landscape of Prognostic Risk Models. Interventional Cardiology Review, 2018, 13, 112.	0.7	20
164	Quo vadis, aspirin?. EuroIntervention, 2018, 14, e1153-e1157.	1.4	2
165	Twitterature. EuroIntervention, 2018, 14, e959-e961.	1.4	14
166	Clinical use of intracoronary imaging. Part 1: guidance and optimization of coronary interventions. An expert consensus document of the European Association of Percutaneous Cardiovascular Interventions. EuroIntervention, 2018, 14, 656-677.	1.4	92
167	Planning Coronary Intervention: The â€œGolden Rulesâ€â€”Patient Checklist and Troubleshooting. , 2018, , 103-117.		0
168	Aspirin Desensitization in Patients With Coronary Artery Disease. Circulation: Cardiovascular Interventions, 2017, 10, .	1.4	43
169	Tailoring duration of DAPT with risk scores. Lancet, The, 2017, 389, 987-989.	6.3	46
170	Bioresorbable Everolimus-Eluting Vascular Scaffold for Long Coronary Lesions. JACC: Cardiovascular Interventions, 2017, 10, 560-568.	1.1	16
171	No Benefit of Different Drug or Design on Clinical Outcomes of First-Generation Polymeric Scaffolds. JACC: Cardiovascular Interventions, 2017, 10, 486-488.	1.1	0
172	Antiplatelet Therapy After Implantation ofÂBioresorbable Vascular Scaffolds. JACC: Cardiovascular Interventions, 2017, 10, 425-437.	1.1	46
173	A Risk Model for Prediction of 1-Year Mortality in Patients Undergoing MitraClip Implantation. American Journal of Cardiology, 2017, 119, 1443-1449.	0.7	31
174	Feasibility and predictors of early discharge after percutaneous edge-to-edge mitral valve repair. Heart, 2017, 103, 931-936.	1.2	7
175	Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement. Annals of Internal Medicine, 2017, 166, 606.	2.0	1
176	Strategies and Outcomes of Repeat Mitral Valve Interventions after Failed MitraClip Therapy. Cardiology, 2017, 137, 114-120.	0.6	6
177	Preventive Strategies for Contrast-Induced Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Procedures. Circulation: Cardiovascular Interventions, 2017, 10, .	1.4	63
178	Late thrombotic events after bioresorbable scaffold implantation: a systematic review and meta-analysis of randomized clinical trials. European Heart Journal, 2017, 38, 2559-2566.	1.0	42
179	Antithrombotic Therapy for Prevention ofÂCerebral Thromboembolic Events After Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2017, 10, 1366-1369.	1.1	20
180	Triple Antithrombotic Therapy atÂtheÂIntercept Between Threats andÂOpportunities. JACC: Cardiovascular Interventions, 2017, 10, 1086-1088.	1.1	15

#	Article	IF	Citations
181	Unusual interatrial membrane in the left atrium: A newer obstacle for transseptalâ€based percutaneous mitral valve repair techniques?. Echocardiography, 2017, 34, 1379-1381.	0.3	0
182	Atrial Fibrillation on Vitamin K Antagonist Undergoing Primary Percutaneous Coronary Intervention for Acute ST-Elevation Myocardial Infarction. , 2017, , 79-94.		0
183	Fate of Nonculprit Plaques in Patients With STEMI Undergoing Primary PCI Followed by Statin Therapy. JACC: Cardiovascular Imaging, 2017, 10, 827-829.	2.3	3
184	Hot topics in transcatheter aortic valve implantation. Future Cardiology, 2017, 13, 503-506.	0.5	1
185	Effects of statin therapy on platelet reactivity after percutaneous coronary revascularization in patients with acute coronary syndrome. Journal of Thrombosis and Thrombolysis, 2017, 44, 355-361.	1.0	9
186	Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves: a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal, 2017, 38, 3382-3390.	1.0	335
187	Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves: a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). European Journal of Cardio-thoracic Surgery, 2017, 52, 408-417.	0.6	160
188	Optimized Screening of Coronary Artery Disease With Invasive Coronary Angiography and Ad Hoc Percutaneous Coronary Intervention During Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2017, 10, .	1.4	25
189	Clinical Outcomes Following IntravascularÂImaging-Guided Versus Coronary Angiographyâ€“Guided Percutaneous Coronary Intervention WithÂStent Implantation. JACC: Cardiovascular Interventions, 2017, 10, 2488-2498.	1.1	209
190	Reply. JACC: Cardiovascular Interventions, 2017, 10, 1275-1276.	1.1	0
191	Transcatheter Aortic Valve Implantation With or Without Percutaneous Coronary Artery Revascularization Strategy: A Systematic Review and Metaâ€Analysis. Journal of the American Heart Association, 2017, 6, .	1.6	116
192	Impact of overlapping on 1â€year clinical outcomes in patients undergoing everolimusâ€eluting bioresorbable scaffolds implantation in routine clinical practice: Insights from the European multicenter GHOSTâ€EU registry. Catheterization and Cardiovascular Interventions, 2017, 89, 812-818.	0.7	15
193	Bioresorbable vascular scaffold use for coronary bifurcation lesions: A substudy from GHOST EU registry. Catheterization and Cardiovascular Interventions, 2017, 89, 47-56.	0.7	28
194	Antiplatelet therapy and outcome in patients undergoing surgery following coronary stenting: Results of the surgery after stenting registry. Catheterization and Cardiovascular Interventions, 2017, 89, E13-E25.	0.7	21
195	Pretreatment with Antiplatelet Agents in the Setting of Percutaneous Coronary Intervention. Interventional Cardiology Clinics, 2017, 6, 13-24.	0.2	6
196	Antiplatelet and Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Coronary Stenting. Interventional Cardiology Clinics, 2017, 6, 91-117.	0.2	4
197	Procedural Management of Patients With Advanced Heart Failure Undergoing MitraClip Implantation (From the GRASP Registry). Journal of Cardiothoracic and Vascular Anesthesia, 2017, 31, e6-e8.	0.6	11
198	Risk stratification with the DAPT score: Carefully read the instructions and use as intended. Thrombosis and Haemostasis, 2017, 117, 1836-1839.	1.8	4

#	Article	IF	Citations
199	Triaging patients with left main disease after the EXCEL and NOBLE trials: the everlasting saga of coronary artery bypass grafting and percutaneous coronary intervention. Journal of Thoracic Disease, 2017, 9, 2766-2770.	0.6	0
200	Heparin versus bivalirudin for percutaneous coronary intervention: has the debate come to an end?. Journal of Thoracic Disease, 2017, 9, 4305-4307.	0.6	2
201	Coronary revascularization strategies in patients with multivessel disease: is it all about diabetes?. Cardiovascular Diagnosis and Therapy, 2017, 7, E1-E3.	0.7	2
202	The DELTA 2 Registry. JACC: Cardiovascular Interventions, 2017, 10, 2401-2410.	1.1	41
203	Trancatheter aortic valve implantation and mitral valve repair: two trains, two speeds. EuroIntervention, 2017, 12, 1921-1924.	1.4	4
204	Late Self-Apposition With One-Year Persisting Uncoverage of Malapposed Bioresorbable Polymeric Struts. Canadian Journal of Cardiology, 2017, 33, 951.e5-951.e6.	0.8	0
205	Assessing Risk in Patients with Stable Coronary Disease: When Should We Intensify Care and Follow-Up? Results from a Meta-Analysis of Observational Studies of the COURAGE and FAME Era. Scientifica, 2016, 2016, 1-10.	0.6	28
206	Overlapping meta-analyses of bioresorbable vascular scaffolds versus everolimus-eluting stents: bringing clarity or confusion?. Journal of Thoracic Disease, 2016, 8, 1366-1370.	0.6	3
207	Early results of MitraClip system implantation by real-time three-dimensional speckle-tracking left ventricle analysis. Journal of Cardiovascular Medicine, 2016, 17, 843-849.	0.6	9
208	Everolimusâ€eluting bioresorbable vascular scaffolds versus second generation drugâ€eluting stents for percutaneous treatment of chronic total coronary occlusions: Technical and procedural outcomes from the G<scp>HOSTâ€CTO</scp> registry. Catheterization and Cardiovascular Interventions, 2016, 88, E155-E163.	0.7	11
209	Impact of Culprit Plaque and Atherothrombotic Components on Incomplete Stent Apposition in Patients With ST-Elevation Myocardial Infarction Treated With Everolimus-Eluting Stentsã€€â€“ An OCTAVIA Substudy â€“. Circulation Journal, 2016, 80, 895-905.	0.7	5
210	Revascularization of Unprotected Left Main Coronary Artery Disease. Circulation: Cardiovascular Interventions, 2016, 9, .	1.4	4
211	Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement. Annals of Internal Medicine, 2016, 165, 334.	2.0	102
212	Real-world cost effectiveness of MitraClip combined with Medical Therapy Versus Medical therapy alone in patients with moderate or severe mitral regurgitation. International Journal of Cardiology, 2016, 209, 153-160.	0.8	37
213	Radial Access Reduces Mortality in Patients With Acute Coronary Syndromes. JACC: Cardiovascular Interventions, 2016, 9, 660-670.	1.1	86
214	Is the Metallic Stent a Safe Treatment for Bioresorbable Scaffold Failure?. JACC: Cardiovascular Interventions, 2016, 9, 976-977.	1.1	0
215	Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary PCI: An updated meta-analysis of 10,350 patients from five randomized clinical trials. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 253-262.	0.4	66
216	Armazones bioabsorbibles y regresiÃ³n de la placa: subir el listÃ³n en la tierra prometida del tratamiento de restauraciÃ³n vascular. Revista Espanola De Cardiologia, 2016, 69, 91-93.	0.6	2

#	Article	IF	Citations
217	Optimal P2Y 12 Inhibitor for Primary Percutaneous Coronary Intervention inÂST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions, 2016, 9, 1047-1050.	1.1	2
218	Bioresorbable Scaffolds and Plaque Regression: Raising the Bar in the Promised Land of Vascular Restoration Therapy. Revista Espanola De Cardiologia (English Ed), 2016, 69, 91-93.	0.4	2
219	New-onset atrial fibrillation and increased mortality after transcatheter aortic valve implantation: A causal or spurious association?. International Journal of Cardiology, 2016, 203, 264-266.	0.8	24
220	Reply. JACC: Cardiovascular Interventions, 2016, 9, 1518-1519.	1.1	0
221	Percutaneous mitral valve repair with the MitraClip system in the elderly: One-year outcomes from the GRASP registry. International Journal of Cardiology, 2016, 224, 440-446.	0.8	19
222	Management issues of chronic therapy with non-vitamin K oral anticoagulants or antiplatelet agents: Different or alike?. International Journal of Cardiology, 2016, 221, 695-696.	0.8	2
223	Aspirin for Primary Cardiovascular Risk Prevention and Beyond in Diabetes Mellitus. Circulation, 2016, 134, 1579-1594.	1.6	107
224	Joint EACVI HIT/EAPCI young survey/ESC CoT survey: training and education for â€˜multimodality imaging in structural interventionsâ€™: the rise of a new sub-specialty?. European Heart Journal Cardiovascular Imaging, 2016, 17, 1432-1433.	0.5	7
225	Bioresorbable Scaffolds. Interventional Cardiology Clinics, 2016, 5, 357-363.	0.2	6
226	Very late outcomes of drug-eluting stents: the â€˜catch-downâ€™ phenomenon. European Heart Journal, 2016, 37, 3396-3398.	1.0	7
227	Antithrombotic therapy for secondary prevention of atherothrombotic events in cerebrovascular disease. Nature Reviews Cardiology, 2016, 13, 609-622.	6.1	24
228	MitraClip Implantation for the Treatment of New-Onset Systolic Anterior Motion of the Mitral Valve After Transcatheter Aortic Valve Replacement. Annals of Thoracic Surgery, 2016, 102, e517-e519.	0.7	7
229	Computing Methods for Composite ClinicalÂEndpoints in Unprotected Left Main Coronary Artery Revascularization. JACC: Cardiovascular Interventions, 2016, 9, 2280-2288.	1.1	26
230	Risk stratification after ST-segment elevation myocardial infarction. Expert Review of Cardiovascular Therapy, 2016, 14, 1349-1360.	0.6	5
231	Update on clinical evidence (Part II): A summary of the main post market studies. Catheterization and Cardiovascular Interventions, 2016, 88, 31-37.	0.7	0
232	Risk prediction of contrast-induced nephropathy by ACEF score in patients undergoing coronary catheterization. Journal of Cardiovascular Medicine, 2016, 17, 524-529.	0.6	17
233	Revisiting the Network ofÂDrug-ElutingÂStent Trials. JACC: Cardiovascular Interventions, 2016, 9, 1213-1215.	1.1	1
234	Impact of residual platelet reactivity on reperfusion in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 475-486.	0.4	15

#	Article	IF	Citations
235	Antithrombotic therapy following transcatheter aortic valve implantation: what challenge do we face?. Expert Review of Cardiovascular Therapy, 2016, 14, 381-389.	0.6	8
236	1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents. JACC: Cardiovascular Interventions, 2016, 9, 440-449.	1.1	23
237	Embolization of Fractured BioresorbableÂScaffold Struts. JACC: Cardiovascular Interventions, 2016, 9, e37-e38.	1.1	2
238	Risk Stratification for Percutaneous Coronary Intervention. Interventional Cardiology Clinics, 2016, 5, 249-257.	0.2	7
239	Reviewing the controversy surrounding pre-treatment with P2Y12inhibitors in acute coronary syndrome patients. Expert Review of Cardiovascular Therapy, 2016, 14, 811-820.	0.6	13
240	Prosthesis choice for transcatheter aortic valve replacement: Improved outcomes with the adoption of a patient-specific transcatheter heart valve selection algorithm. International Journal of Cardiology, 2016, 203, 1009-1010.	0.8	7
241	Long-term EXAMINATION of drug-eluting stents in acute myocardial infarction. Lancet, The, 2016, 387, 316-318.	6.3	1
242	Usefulness of 3D OCT to Diagnose a Noncircumferential Open-Cell Stent Fracture. JACC: Cardiovascular Imaging, 2016, 9, 210-211.	2.3	5
243	Bioresorbable scaffolds for calcified lesions: not a free lunch!. EuroIntervention, 2016, 11, 1334-1336.	1.4	1
244	Impact of chronic kidney disease on outcomes after percutaneous mitral valve repair with the MitraClip system: insights from the GRASP registry. EuroIntervention, 2016, 11, e1649-e1657.	1.4	24
245	One-year outcomes after Absorb bioresorbable vascular scaffold implantation in routine clinical practice. EuroIntervention, 2016, 12, e152-e159.	1.4	7
246	Relationship between diabetes, platelet reactivity, and the SYNTAX score to one-year clinical outcome in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention. EuroIntervention, 2016, 12, 312-318.	1.4	27
247	Long-term clinical outcomes after percutaneous coronary intervention versus coronary artery bypass grafting for acute coronary syndrome from the DELTA registry: a multicentre registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment. EuroIntervention, 2016, 12, e623-e631.	1.4	17
248	Transcatheter aortic valve durability and the dark side of Kaplan-Meier analysis. EuroIntervention, 2016, 12, 821-822.	1.4	5
249	Upcoming TAVI trials: rationale, design and impact on clinical practice. EuroIntervention, 2016, 12, Y51-Y55.	1.4	13
250	Early and midterm outcomes of bioresorbable vascular scaffolds for ostial coronary lesions: insights from the GHOST-EU registry. EuroIntervention, 2016, 12, e550-e556.	1.4	32
251	Long-term antithrombotic pharmacotherapy following ST-elevation myocardial infarction. Minerva Cardioangiologica, 2016, 64, 305-21.	1.2	1
252	Current Status and Clinical Development of Transcatheter Approaches for Severe Mitral Regurgitation. Circulation Journal, 2015, 79, 1164-1171.	0.7	19

#	Article	IF	Citations
253	Radial Versus Femoral Access in Invasively Managed Patients With Acute Coronary Syndrome. Annals of Internal Medicine, 2015, 163, 932-940.	2.0	83
254	Bivalirudin for acute coronary syndromes: premises, promises and doubts. Thrombosis and Haemostasis, 2015, 113, 698-707.	1.8	14
255	Anatomical features and management of bioresorbable vascular scaffolds failure: A case series from the <scp>GHOST</scp> registry. Catheterization and Cardiovascular Interventions, 2015, 85, 1150-1161.	0.7	32
256	Impact of bridging with perioperative low-molecular-weight heparin on cardiac and bleeding outcomes of stented patients undergoing non-cardiac surgery. Thrombosis and Haemostasis, 2015, 114, 423-431.	1.8	26
257	Antithrombotic treatment in patients undergoing transcatheter aortic valve implantation (TAVI). Thrombosis and Haemostasis, 2015, 113, 674-685.	1.8	32
258	Perioperative management of oral antiplatelet therapy and clinical outcomes in coronary stent patients undergoing surgery. Thrombosis and Haemostasis, 2015, 113, 272-282.	1.8	46
259	New insights on acute expansion and longitudinal elongation of bioresorbable vascular scaffolds in vivo and at bench test: A note of caution on reliance to compliance charts and nominal length. Catheterization and Cardiovascular Interventions, 2015, 85, E99-E107.	0.7	9
260	Management of adjunctive antithrombotic therapy in STEMI patients treated with fibrinolysis undergoing rescue or delayed PCI. Thrombosis and Haemostasis, 2015, 114, 945-957.	1.8	1
261	Eroded Versus Ruptured Plaques at the Culprit Site of STEMI. JACC: Cardiovascular Imaging, 2015, 8, 566-575.	2.3	88
262	Clinical, Angiographic, Functional, andÂImaging Outcomes 12 Months AfterÂImplantation of Drug-Eluting Bioresorbable Vascular Scaffolds in AcuteÂCoronary Syndromes. JACC: Cardiovascular Interventions, 2015, 8, 770-777.	1.1	38
263	Reply. JACC: Cardiovascular Interventions, 2015, 8, 869-870.	1.1	0
264	Fate of Coronary Chronic Total Occlusion Recanalization via Subintimal Tracking WithÂBioresorbable Vascular Scaffolds: A Temporary Cage for a Permanent New Lumen?. JACC: Cardiovascular Imaging, 2015, 8, 1114-1115.	2.3	0
265	Extended Use of Percutaneous Edge-to-Edge Mitral Valve Repair BeyondÂEVEREST (Endovascular Valve) Tj ETQq1 1 0.784314 rgBT /O	1.1	106
266	Triple Therapy for Atrial Fibrillation and ACS With or Without PCI. Journal of the American College of Cardiology, 2015, 65, 515-516.	1.2	9
267	Optical Coherence Tomography Assessment of Late Intra-Scaffold Dissection. JACC: Cardiovascular Interventions, 2015, 8, e11-e12.	1.1	3
268	Moderate and Severe Preoperative Chronic Kidney Disease Worsen Clinical Outcomes After Transcatheter Aortic Valve Implantation. Circulation: Cardiovascular Interventions, 2015, 8, e002220.	1.4	73
269	Impact of postoperative acute kidney injury on clinical outcomes after transcatheter aortic valve implantation: A metaâ€analysis of 5,971 patients. Catheterization and Cardiovascular Interventions, 2015, 86, 518-527.	0.7	75
270	Morphine Is Associated With a Delayed Activity of Oral Antiplatelet Agents in Patients With ST-Elevation Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2015, 8, .	1.4	164

#	Article	IF	Citations
271	Meta-Analysis of Randomized Controlled Trials and Adjusted Observational Results of Use of Clopidogrel, Aspirin, and Oral Anticoagulants in Patients Undergoing Percutaneous Coronary Intervention. American Journal of Cardiology, 2015, 115, 1185-1193.	0.7	65
272	Pretreatment With Antiplatelet Drugs in Invasively Managed Patients With Coronary Artery Disease in the Contemporary Era. Circulation: Cardiovascular Interventions, 2015, 8, e002301.	1.4	58
273	Residual platelet reactivity to predict long-term clinical outcomes after clopidogrel loading in patients with acute coronary syndromes: comparison of different cutoff values by light transmission aggregometry from the responsiveness to clopidogrel and stent thrombosis 2-acute coronary syndrome (RECLOSE 2-ACS) study. Journal of Thrombosis and Thrombolysis, 2015, 40, 76-82.	1.0	27
274	Five-year outcomes of percutaneous coronary intervention versus coronary artery bypass graft surgery in patients with left main coronary artery disease: An updated meta-analysis of randomized trials and adjusted observational studies. International Journal of Cardiology, 2015, 195, 79-81.	0.8	22
275	Cyphering the Mechanism of Late Failure of Bioresorbable Vascular Scaffolds in Percutaneous Coronary Intervention of the Left Main Coronary Artery. JACC: Cardiovascular Interventions, 2015, 8, e95-e97.	1.1	1
276	Early discharge after transfemoral transcatheter aortic valve implantation. Heart, 2015, 101, 1485-1490.	1.2	80
277	Ventricular arrhythmias in aortic valve stenosis before and after transcatheter aortic valve implantation. Europace, 2015, 17, 1136-1140.	0.7	30
278	SYNTAX Score II predicts carotid disease in a multivessel coronary disease population. International Journal of Cardiology, 2015, 196, 145-148.	0.8	5
279	One-Year Coverage by Optical Coherence Tomography of a Bioresorbable Scaffold Neocarina: Is It Safe to Discontinue Dual-Antiplatelet Therapy?. Canadian Journal of Cardiology, 2015, 31, 1205.e5-1205.e6.	0.8	0
280	Predictors of clinical outcomes after edge-to-edge percutaneous mitral valve repair. American Heart Journal, 2015, 170, 187-195.	1.2	90
281	New-Onset Coronary Aneurism and Late-Acquired Incomplete Scaffold Apposition After Full Polymer Jacket ofÂaÂChronic Total Occlusion With Bioresorbable Scaffolds. JACC: Cardiovascular Interventions, 2015, 8, e41-e43.	1.1	9
282	Neoatherosclerosis as the Cause of LateÂFailure of a Bioresorbable VascularÂScaffold. JACC: Cardiovascular Interventions, 2015, 8, 633-634.	1.1	11
283	Impact of moderate preoperative chronic kidney disease on mortality after transcatheter aortic valve implantation. International Journal of Cardiology, 2015, 189, 77-78.	0.8	5
284	Impact of P2Y12-mediated platelet reactivity on myocardial perfusion of patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a cardiac magnetic resonance study. Journal of Cardiovascular Magnetic Resonance, 2015, 17, P152.	1.6	0
285	Longitudinal Elongation, Axial Compression, and Effects on StrutÂGeometry of Bioresorbable VascularÂScaffolds. JACC: Cardiovascular Interventions, 2015, 8, e35-e37.	1.1	3
286	Effectiveness of MitraClip Therapy in Patients with Refractory Heart Failure. Journal of Interventional Cardiology, 2015, 28, 61-68.	0.5	19
287	A multidisciplinary consensus document on followâ€up strategies for patients treated with percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2015, 85, E129-39.	0.7	6
288	Reply to the letter. Journal of Cardiovascular Medicine, 2015, 16, 73.	0.6	0

#	Article	IF	Citations
289	Meta-Analyses of Dual Antiplatelet Therapy Following Drug-Eluting Stent Implantation. Journal of the American College of Cardiology, 2015, 66, 1639-1640.	1.2	32
290	Managing Bioabsorbable Vascular Scaffold Failure: Combined Scaffold Restenosis and Late-Acquired Coronary Aneurysm Treated With Self-Expandable Stent. Canadian Journal of Cardiology, 2015, 31, 691.e1-691.e3.	0.8	9
291	Acute Kidney Injury With the RenalGuard System in Patients Undergoing Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2015, 8, 1595-1604.	1.1	108
292	2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Europace, 2015, 17, euv319.	0.7	635
293	Risk stratification for secondary prevention with ticagrelor and aspirin: A closer look to patient subsets from the PEGASUS-TIMI 54 trial. International Journal of Cardiology, 2015, 201, 276-278.	0.8	3
294	Predictive accuracy of CHA2DS2-VASc and HAS-BLED scores in patients without atrial fibrillation undergoing percutaneous coronary intervention and discharged on dual antiplatelet therapy. International Journal of Cardiology, 2015, 199, 319-325.	0.8	39
295	Revisiting Sex Equality With Transcatheter Aortic Valve Replacement Outcomes. Journal of the American College of Cardiology, 2015, 66, 221-228.	1.2	183
296	Treatment strategies for coronary in-stent restenosis: systematic review and hierarchical Bayesian network meta-analysis of 24 randomised trials and 4880 patients. BMJ, The, 2015, 351, h5392.	3.0	102
297	Comparison of Three Contemporary Surgical Scores for Predicting All-Cause Mortality of Patients Undergoing Percutaneous Mitral Valve Repair With the MitraClip System (from the Multicenter) Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.4	40
298	Genderâ€related clinical and echocardiographic outcomes at 30â€day and 12â€month follow up after <scp>M</scp>itra<scp>C</scp>lip implantation in the <scp>GRASP</scp> registry. Catheterization and Cardiovascular Interventions, 2015, 85, 889-897.	0.7	44
299	Triple antithrombotic therapy in atrial fibrillation patients with acute coronary syndromes or undergoing percutaneous coronary intervention or transcatheter aortic valve replacement. EuroIntervention, 2015, 10, 1015-1021.	1.4	21
300	Comparison of suture-based vascular closure devices in transfemoral transcatheter aortic valve implantation. EuroIntervention, 2015, 11, 690-697.	1.4	48
301	Lessons from the GHOST-EU registry. EuroIntervention, 2015, 11, V170-V174.	1.4	17
302	What about the risk of thrombosis with bioresorbable scaffolds?. EuroIntervention, 2015, 11, V181-V184.	1.4	23
303	Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention, 2015, 10, 1144-1153.	1.4	411
304	One-year outcomes in unselected patients treated with a thin-strut, platinum-chromium, paclitaxel-eluting stent: primary endpoint results from the TAXUS Element European post-approval surveillance study (TE-PROVE). EuroIntervention, 2015, 10, 1261-1266.	1.4	5
305	Contemporary practice and technical aspects in coronary intervention with bioresorbable scaffolds: a European perspective. EuroIntervention, 2015, 11, 45-52.	1.4	131
306	Incidence and potential mechanism of resolved, persistent and newly acquired malapposition three days after implantation of self-expanding or balloon-expandable stents in a STEMI population: insights from optical coherence tomography in the APPOSITION II study. EuroIntervention, 2015, 11, 885-894.	1.4	14

#	Article	IF	Citations
307	The EAPCI and continuing education for Fellows. EuroIntervention, 2015, 10, 1258-1259.	1.4	0
308	Three-Dimensional Angle Assessment and Plaque Distribution Classification in Left Main Disease: Impact of Geometry on Outcome. Reviews in Cardiovascular Medicine, 2015, 16, 131-139.	0.5	0
309	Non-Hemodynamically Significant Renal Artery Stenosis Predicts Cardiovascular Events in Persons with Ischemic Heart Disease. American Journal of Nephrology, 2014, 40, 468-477.	1.4	13
310	Association of tricuspid regurgitation with clinical and echocardiographic outcomes after percutaneous mitral valve repair with the MitraClip System: 30-day and 12-month follow-up from the GRASP Registry. European Heart Journal Cardiovascular Imaging, 2014, 15, 1246-1255.	0.5	125
311	Impact of Gene Polymorphisms, PlateletÂReactivity, and the SYNTAX Score on 1-Year Clinical Outcomes in PatientsÂWithÂNonâ€“ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2014, 7, 1117-1127.	1.1	38
312	Updates on NSAIDs in patients with and without coronary artery disease: pitfalls, interactions and cardiovascular outcomes. Expert Review of Cardiovascular Therapy, 2014, 12, 1185-1203.	0.6	23
313	Usefulness and Validation of the Survival posT TAVI Score for SurvivalÂAfter Transcatheter Aortic Valve Implantation forÂAortic Stenosis. American Journal of Cardiology, 2014, 114, 1867-1874.	0.7	30
314	The SYNTAX score does not predict presence of carotid disease in a multivessel coronary disease population. Catheterization and Cardiovascular Interventions, 2014, 83, 1169-1175.	0.7	12
315	Positive airway pressure in patients with coronary artery disease and obstructive sleep apnea syndrome. Journal of Cardiovascular Medicine, 2014, 15, 402-406.	0.6	21
316	Bioprosthetic Valves for Transcatheter Aortic Valve Replacement. JAMA - Journal of the American Medical Association, 2014, 312, 843.	3.8	0
317	Long-Term Clinical Outcomes After Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting for Ostial/Midshaft Lesions in Unprotected Left Main Coronary Artery From the DELTA Registry. JACC: Cardiovascular Interventions, 2014, 7, 354-361.	1.1	45
318	CABG versus PCI in diabetic patients with multivessel disease after risk stratification by the SYNTAX score: A pooled analysis of the SYNTAX and FREEDOM trials. International Journal of Cardiology, 2014, 173, 548-549.	0.8	5
319	Comparison of Percutaneous Coronary Intervention (With Drug-Eluting Stents) Versus Coronary Artery Bypass Grafting in Women With Severe Narrowing of the Left Main Coronary Artery (from the) Tj ETQq1 1 0.784314 rgBT /Ove Cardiology, 2014, 113, 1348-1355.	0.7	14
320	Bridging antiplatelet therapy in patients requiring cardiac and non-cardiac surgery: from bench to bedside. Journal of Cardiovascular Translational Research, 2014, 7, 82-90.	1.1	5
321	Management of Antiplatelet and Anticoagulant Therapy in Patients With Atrial Fibrillation in the Setting of Acute Coronary Syndromes or Percutaneous Coronary Interventions. Circulation: Cardiovascular Interventions, 2014, 7, 113-124.	1.4	67
322	Volumeâ€toâ€creatinine clearance ratio in patients undergoing coronary angiography with or without percutaneous coronary intervention: Implications of varying definitions of contrastâ€induced nephropathy. Catheterization and Cardiovascular Interventions, 2014, 83, 907-912.	0.7	21
323	Spontaneous coronary artery dissection. International Journal of Cardiology, 2014, 175, 8-20.	0.8	82
324	Acute Left Atrial Spontaneous Echocardiographic Contrast and Suspicious Thrombus Formation Following Mitral Regurgitation Reduction With the MitraClip System. JACC: Cardiovascular Interventions, 2014, 7, 1322-1323.	1.1	11

#	Article	IF	Citations
325	Mechanisms of Atherothrombosis andÂVascular Response to Primary Percutaneous Coronary Intervention inÂWomen Versus Men With AcuteÂMyocardial Infarction. JACC: Cardiovascular Interventions, 2014, 7, 958-968.	1.1	89
326	Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm So. European Heart Journal, 2014, 35, 3155-3179.	1.0	490
327	Mechanisms, Pathophysiology, and Clinical Aspects of Incomplete Stent Apposition. Journal of the American College of Cardiology, 2014, 63, 1355-1367.	1.2	109
328	Impact of Balloon Post-Dilation on ClinicalÂOutcomes After Transcatheter Aortic Valve Replacement With the Self-Expanding CoreValve Prosthesis. JACC: Cardiovascular Interventions, 2014, 7, 1014-1021.	1.1	47
329	Residual platelet reactivity and outcomes with 5mg prasugrel therapy in elderly patients undergoing percutaneous coronary intervention. International Journal of Cardiology, 2014, 176, 874-877.	0.8	8
330	A Simple Risk Tool (the OBSERVANT Score) for Prediction of 30-Day Mortality After Transcatheter Aortic Valve Replacement. American Journal of Cardiology, 2014, 113, 1851-1858.	0.7	126
331	Percutaneous Mitral Valve Repair With the MitraClip System for Severe Mitral Regurgitation in Patients With Surgical Mitral Valve Repair Failure. Journal of the American College of Cardiology, 2014, 63, 836-838.	1.2	33
332	Prognostic Indicators for Recurrent Thrombotic Events in HIV-infected Patients with Acute Coronary Syndromes: Use of Registry Data From 12 sites in Europe, South Africa and the United States. Thrombosis Research, 2014, 134, 558-564.	0.8	44
333	Meta-Analysis of Randomized Controlled Trials of Preprocedural Statin Administration for Reducing Contrast-Induced Acute Kidney Injury in Patients Undergoing Coronary Catheterization. American Journal of Cardiology, 2014, 114, 541-548.	0.7	44
334	Preoperative Fibrinogen and Morbidity in Patients With Residual Platelet Inhibition Undergoing Off-Pump Coronary Artery Bypass Grafting. Circulation Journal, 2014, 78, 1571-1573.	0.7	0
335	Perioperative management of antiplatelet therapy in patients with coronary stents undergoing cardiac and non-cardiac surgery: a consensus document from Italian cardiological, surgical and anaesthesiological societies. EuroIntervention, 2014, 10, 38-46.	1.4	119
336	Usefulness of contrast injection during balloon aortic valvuloplasty before transcatheter aortic valve replacement: a pilot study. EuroIntervention, 2014, 10, 241-247.	1.4	14
337	Updating the evidence on patent foramen ovale closure versus medical therapy in patients with cryptogenic stroke: a systematic review and comprehensive meta-analysis of 2,303 patients from three randomised trials and 2,231 patients from 11 observational studies. EuroIntervention, 2014, 9, 1342-1349.	1.4	50
338	Emerging strategies for rapid reversal of anticoagulation in patients undergoing catheter-based interventions: aptamers enter the RADAR. EuroIntervention, 2014, 10, 425-427.	1.4	0
339	Impact of different stent alloys on human vascular response to everolimusâ€eluting stent: An optical coherence tomography study: The OCTEVEREST. Catheterization and Cardiovascular Interventions, 2013, 81, 510-518.	0.7	27
340	Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: Impact of high onâ€treatment platelet reactivity and diabetes mellitus status. Catheterization and Cardiovascular Interventions, 2013, 81, 42-49.	0.7	18
341	Optical coherence tomography guided in-stent thrombus removal in patients with acute coronary syndromes. International Journal of Cardiovascular Imaging, 2013, 29, 989-996.	0.7	19
342	Incidence, Predictors, and Outcomes of Aortic Regurgitation After Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2013, 61, 1585-1595.	1.2	702

#	Article	IF	Citations
343	Impact of renal function on clopidogrel-induced antiplatelet effects in coronary artery disease patients without diabetes mellitus. Journal of Thrombosis and Thrombolysis, 2013, 36, 14-17.	1.0	14
344	Left ventricular reverse remodeling after transcatheter aortic valve implantation: a cardiovascular magnetic resonance study. Journal of Cardiovascular Magnetic Resonance, 2013, 15, 39.	1.6	29
345	Long-Term Outcomes of Patients With Acute Coronary Syndrome and Nonobstructive Coronary Artery Disease. American Journal of Cardiology, 2013, 112, 150-155.	0.7	66
346	Prevalence of renal artery stenosis in patients undergoing cardiac catheterization. Internal and Emergency Medicine, 2013, 8, 401-408.	1.0	11
347	Meta-analysis of everolimus-eluting stents versus first-generation drug-eluting stents in patients with left main coronary artery undergoing percutaneous coronary intervention. International Journal of Cardiology, 2013, 168, 1718-1719.	0.8	6
348	Early and long-term outlook of percutaneous coronary intervention for bifurcation lesions in young patients. International Journal of Cardiology, 2013, 167, 2995-2999.	0.8	4
349	Gender-related differences of diabetic patients undergoing percutaneous coronary intervention with drug-eluting stents: A real-life multicenter experience. International Journal of Cardiology, 2013, 168, 139-143.	0.8	12
350	Are the Culprit Lesions Severely Stenotic?. JACC: Cardiovascular Imaging, 2013, 6, 1108-1114.	2.3	31
351	Management of Antiplatelet Therapy in Patients With Coronary Artery Disease Requiring Cardiac and Noncardiac Surgery. Circulation, 2013, 128, 2785-2798.	1.6	91
352	Long-Term Clinical Outcomes After Percutaneous Coronary Intervention for Ostial/Mid-Shaft Lesions Versus Distal Bifurcation Lesions in Unprotected LeftÂMain Coronary Artery. JACC: Cardiovascular Interventions, 2013, 6, 1242-1249.	1.1	75
353	Paclitaxel versus sirolimus eluting stents in diabetic patients: Does stent type and/or stent diameter matter?: Longâ€term clinical outcome of 2,429â€patient multicenter registry. Catheterization and Cardiovascular Interventions, 2013, 81, 80-89.	0.7	15
354	Effects of cangrelor in coronary artery disease patients with and without diabetes mellitus: an in vitro pharmacodynamic investigation. Journal of Thrombosis and Thrombolysis, 2013, 35, 155-164.	1.0	24
355	Initial experience of percutaneous coronary intervention in bifurcations with bioresorbable vascular scaffolds using different techniques â€" Insights from optical coherence tomography. International Journal of Cardiology, 2013, 170, e33-e35.	0.8	3
356	Antithrombotic Strategies in Valvular and Structural Heart Disease Interventions. Interventional Cardiology Clinics, 2013, 2, 635-642.	0.2	2
357	Incorporating Glomerular filtration rate or creatinine clearance by the modification of diet in renal disease equation or the Cockcroftâ€"Gault equations to improve the Global Accuracy of the Age, Creatinine, Ejection Fraction [ACEF] score in patients undergoing percutaneous coronary intervention. International Journal of Cardiology, 2013, 168, 396-402.	0.8	23
358	First-in-human description of everolimus-eluting bioabsorbable vascular scaffold implantation for the treatment of drug-eluting stent failure: Insights from optical coherence tomography. International Journal of Cardiology, 2013, 168, 4490-4491.	0.8	13
359	One- and Twelve-Month Safety and Efficacy Outcomes of Patients Undergoing Edge-to-Edge Percutaneous Mitral Valve Repair (from the GRASP Registry). American Journal of Cardiology, 2013, 111, 1482-1487.	0.7	131
360	EuroSCORE II Versus Additive and Logistic EuroSCORE in Patients Undergoing Percutaneous Coronary Intervention. American Journal of Cardiology, 2013, 112, 323-329.	0.7	14

#	Article	IF	Citations
361	Percutaneous recanalization of chronic total occlusions: Wherein lies the body of proof?. American Heart Journal, 2013, 165, 133-142.	1.2	30
362	Dual antiplatelet therapy in patients with diabetes mellitus: special considerations. Expert Review of Cardiovascular Therapy, 2013, 11, 307-317.	0.6	6
363	Novel oral anticoagulants versus warfarin in non-valvular atrial fibrillation: A meta-analysis of 50,578 patients. International Journal of Cardiology, 2013, 167, 1237-1241.	0.8	79
364	Beyond the SYNTAX Score. Circulation Journal, 2013, 77, 1131-1138.	0.7	25
365	Usefulness of the logistic clinical SYNTAX score for predicting 1â€year mortality in patients undergoing percutaneous coronary intervention of the left main coronary artery. Catheterization and Cardiovascular Interventions, 2013, 82, E446-52.	0.7	6
366	Objectifying the impact of incomplete revascularization by repeat angiographic risk assessment with the residual SYNTAX score after left main coronary artery percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2013, 82, 333-340.	0.7	32
367	Current Status and Ongoing Development of Reversing Agents for Novel Oral Anticoagulants (NOACs). Recent Patents on Cardiovascular Drug Discovery, 2013, 8, 2-9.	1.5	5
368	Pre-defining optimal C-arm position for TAVI with CT-scan using free software. EuroIntervention, 2013, 9, 878-879.	1.4	2
369	Unmet needs of young interventional cardiologists: the EAPCI Young survey. EuroIntervention, 2013, 9, 903-908.	1.4	7
370	Serial Assessment of Coronary Artery Response to Paclitaxel-Eluting Stents Using Optical Coherence Tomography. Circulation: Cardiovascular Interventions, 2012, 5, 30-38.	1.4	26
371	Transcatheter aortic valve implantation: 3-year outcomes of self-expanding CoreValve prosthesis. European Heart Journal, 2012, 33, 969-976.	1.0	265
372	Lost in calculation: the Clinical SYNTAX score goes logistic. European Heart Journal, 2012, 33, 3008-3010.	1.0	7
373	Novel drugs for oral anticoagulation pharmacotherapy. Expert Review of Cardiovascular Therapy, 2012, 10, 473-488.	0.6	6
374	Response to Letter Regarding Article, â€œAntithrombotic Therapy in Patients With Chronic Kidney Diseaseâ€• Circulation, 2012, 126, .	1.6	0
375	Facilitated/Pharmaco-invasive Approaches in STEMI. Current Cardiology Reviews, 2012, 8, 177-180.	0.6	9
376	Effect size of ticagrelor over clopidogrel in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Journal of Cardiovascular Medicine, 2012, 13, 162-163.	0.6	3
377	Safety and efficacy of proteaseâ€activated receptorâ€1 antagonists in patients with coronary artery disease: a metaâ€analysis of randomized clinical trials. Journal of Thrombosis and Haemostasis, 2012, 10, 2006-2015.	1.9	40
378	Impacto del tratamiento adyuvante con cilostazol comparado con dosis altas de mantenimiento de clopidogrel en pacientes con diabetes mellitus y respuesta subÃ³ptima. Revista Espanola De Cardiologia, 2012, 65, 105-106.	0.6	9

#	Article	IF	Citations
379	A focused update on emerging prognostic determinants in distal left main percutaneous coronary intervention. International Journal of Cardiology, 2012, 160, 4-7.	0.8	5
380	Unraveling the EXCEL: Promises and challenges of the next trial of left main percutaneous coronary intervention. International Journal of Cardiology, 2012, 156, 1-3.	0.8	24
381	Does the SYNTAX score get on your nerves? Practical considerations on how and when avoiding it to maximize its usefulness with no waste of time. International Journal of Cardiology, 2012, 159, 165-168.	0.8	7
382	Increasing CHADS2 scores may attenuate the benefit of novel oral anticoagulants versus warfarin in reducing intracranial bleeding. International Journal of Cardiology, 2012, 161, 176-177.	0.8	5
383	Targeting Platelet Nitric Oxide Resistance With Ramipril. Journal of the American College of Cardiology, 2012, 60, 895-897.	1.2	1
384	Cigarette Smoking Is Associated With a Dose-Response Effect in Clopidogrel-Treated Patients With Diabetes Mellitus and Coronary Artery Disease. JACC: Cardiovascular Interventions, 2012, 5, 293-300.	1.1	48
385	Drug-Eluting Stent for Left Main Coronary Artery Disease. JACC: Cardiovascular Interventions, 2012, 5, 718-727.	1.1	121
386	Self-Expanding Versus Balloon-Expandable Stents in Acute Myocardial Infarction: Results From the APPOSITION II Study. JACC: Cardiovascular Interventions, 2012, 5, 1209-1219.	1.1	82
387	Comparative One-Year Effectiveness of Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients <75 Versus â‰¥75 Years With Unprotected Left Main Disease (from the) Tj ETQq1 1 0.784314 rgBT /Ove	1.1	12
388	Antithrombotic Therapy in Patients With Chronic Kidney Disease. Circulation, 2012, 125, 2649-2661.	1.6	127
389	Prognostic implications of early and longâ€term bleeding events in patients on oneâ€year dual antiplatelet therapy following drugâ€eluting stent implantation. Catheterization and Cardiovascular Interventions, 2012, 80, 395-405.	0.7	11
390	Incidence rate and predictors of permanent pacemaker implantation after transcatheter aortic valve implantation with self-expanding CoreValve prosthesis. Journal of Interventional Cardiac Electrophysiology, 2012, 34, 189-195.	0.6	58
391	Comparison of Complications and Outcomes to One Year of Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis. American Journal of Cardiology, 2012, 109, 1487-1493.	0.7	62
392	Effect of Renal Artery Stenting on Left Ventricular Mass: A Randomized Clinical Trial. American Journal of Kidney Diseases, 2012, 60, 39-46.	2.1	45
393	Earlyâ€and midâ€term outcomes of transcatheter aortic valve implantation in patients with logistic EuroSCORE less than 20%: A comparative analysis between different risk strata. Catheterization and Cardiovascular Interventions, 2012, 79, 132-140.	0.7	33
394	Antithrombotic Pharmacotherapy in the Elderly: General Issues and Clinical Conundrums. Current Treatment Options in Cardiovascular Medicine, 2012, 14, 57-68.	0.4	3
395	Safety and effectiveness of the Catania Polyzene-F coated stent in real world clinical practice: 12-month results from the ATLANTA 2 registry. EuroIntervention, 2012, 7, 1062-1068.	1.4	9
396	Impact of Insulin Receptor Substrate-1 Genotypes on Platelet Reactivity and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. Journal of the American College of Cardiology, 2011, 58, 30-39.	1.2	58

#	Article	IF	Citations
397	Impact of Gastric Acidâ€“Suppressing Therapies on Platelet Reactivity in Patients With Coronary Artery Disease Treated With Clopidogrel. Journal of the American College of Cardiology, 2011, 58, 1396-1398.	1.2	8
398	Percutaneous Coronary Intervention Versus Coronary Artery Bypass Graft Surgery in Left Main Coronary Artery Disease. Journal of the American College of Cardiology, 2011, 58, 1426-1432.	1.2	185
399	Impact of Pentoxifylline on Platelet Function Profiles in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and Clopidogrel. JACC: Cardiovascular Interventions, 2011, 4, 905-912.	1.1	17
400	Incidence and Predictors of Early and Late Mortality After Transcatheter Aortic Valve Implantation in 663 Patients With Severe Aortic Stenosis. Circulation, 2011, 123, 299-308.	1.6	1,044
401	Integrating the Synergy between percutaneous coronary intervention with Taxus and Cardiac Surgery (SYNTAX) score into practice: Use, pitfalls, and new directions. American Heart Journal, 2011, 161, 462-470.	1.2	33
402	Are propensity scores really superior to standard multivariable analysis?. Contemporary Clinical Trials, 2011, 32, 731-740.	0.8	206
403	Routine versus selective coronary artery bypass for left main coronary artery revascularization: The appraise a customized strategy for left main revascularization (CUSTOMIZE) study. International Journal of Cardiology, 2011, 150, 307-314.	0.8	1
404	Cyphering the statistical and clinical significance of prasugrel in the TRITON-TIMI 38 trial. International Journal of Cardiology, 2011, 146, 242-243.	0.8	2
405	A post-hoc analysis of the CUSTOMIZE Registry on the differential impact of EuroSCORE and SYNTAX score in left main patients with intermediate Global Risk. International Journal of Cardiology, 2011, 150, 116-117.	0.8	4
406	Daytime sleepiness does not predict sleep apnoea in patients with coronary artery disease. International Journal of Cardiology, 2011, 151, 248-250.	0.8	9
407	Functional profile of the platelet P2Y12 receptor signalling pathway in patients with type 2 diabetes mellitus and coronary artery disease. Thrombosis and Haemostasis, 2011, 105, 730-732.	1.8	34
408	Platelet function profiles in the elderly: Results of a pharmacodynamic study in patients on clopidogrel therapy and effects of switching to prasugrel 5 mg in patients with high platelet reactivity. Thrombosis and Haemostasis, 2011, 106, 1149-1157.	1.8	29
409	Novel drug-eluting stents in the treatment of de novo coronary lesions. Vascular Health and Risk Management, 2011, 7, 103.	1.0	18
410	Haemostatic profiles assessed by thromboelastography in patients with end-stage renal disease. Thrombosis and Haemostasis, 2011, 106, 67-74.	1.8	36
411	Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy. Thrombosis and Haemostasis, 2011, 106, 253-262.	1.8	37
412	Head-to-head comparison of early vessel healing by optical coherence tomography after implantation of different stents in the same patient. Journal of Cardiovascular Medicine, 2011, 12, 328-333.	0.6	10
413	Impact of diabetes mellitus on long-term follow-up of percutaneous coronary intervention based on clinical presentation of coronary artery disease. Journal of Cardiovascular Medicine, 2011, 12, 405-410.	0.6	8
414	Safety of clopidogrel and proton pump inhibitors in patients undergoing drug-eluting stent implantation. Coronary Artery Disease, 2011, 22, 199-205.	0.3	35

#	Article	IF	Citations
415	The Rapid Evaluation of Vessel Healing after Angioplasty (REVEAL) trial. Interventional Cardiology, 2011, 3, 451-460.	0.0	1
416	Does Occlusion Duration Influence Procedural and Clinical Outcome of Patients Who Underwent Percutaneous Coronary Intervention for Chronic Total Occlusion?. Journal of Interventional Cardiology, 2011, 24, 223-231.	0.5	13
417	Prevalence, Predictors, and Long-Term Prognosis of Premature Discontinuation of Oral Antiplatelet Therapy After Drug Eluting Stent Implantation. American Journal of Cardiology, 2011, 107, 186-194.	0.7	113
418	Comparison of One-Year Outcomes of Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With Unprotected Left Main Coronary Artery Disease and Acute Coronary Syndromes (from the CUSTOMIZE Registry). American Journal of Cardiology, 2011, 108, 355-359.	0.7	39
419	Dual Antiplatelet Therapy Versus Aspirin Alone in Patients Undergoing Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2011, 108, 1772-1776.	0.7	231
420	Appraising the impact of left ventricular ejection fraction on outcomes of percutaneous drug-eluting stenting for unprotected left main disease: insights from a multicenter registry of 975 patients. Clinical Research in Cardiology, 2011, 100, 403-411.	1.5	22
421	Is intravascular ultrasound beneficial for percutaneous coronary intervention of bifurcation lesions? Evidence from a 4,314-patient registry. Clinical Research in Cardiology, 2011, 100, 1021-1028.	1.5	38
422	Epidemiology and clinical impact of different anatomical phenotypes of the left main coronary artery. Heart and Vessels, 2011, 26, 138-144.	0.5	10
423	Global Risk Classification and Clinical SYNTAX (Synergy between Percutaneous Coronary Intervention) Tj ETQq1 1 0.784314 rgBT /Ov Revascularization. JACC: Cardiovascular Interventions, 2011, 4, 287-297.	1.1	119
424	Cardiovascular magnetic resonance for the assessment of patients undergoing transcatheter aortic valve implantation: a pilot study. Journal of Cardiovascular Magnetic Resonance, 2011, 13, 82.	1.6	34
425	Validating the EXCEL hypothesis: A propensity score matched 3â€year comparison of percutaneous coronary intervention versus coronary artery bypass graft in left main patients with SYNTAX score â‰¤32. Catheterization and Cardiovascular Interventions, 2011, 77, 936-943.	0.7	25
426	The optimal pharmacological formula for percutaneous coronary intervention. Expert Opinion on Pharmacotherapy, 2011, 12, 1075-1086.	0.9	0
427	Pharmacodynamic Evaluation of Pantoprazole Therapy on Clopidogrel Effects. Circulation: Cardiovascular Interventions, 2011, 4, 273-279.	1.4	35
428	Pharmacodynamic Effects of Different Aspirin Dosing Regimens in Type 2 Diabetes Mellitus Patients With Coronary Artery Disease. Circulation: Cardiovascular Interventions, 2011, 4, 180-187.	1.4	172
429	Reference Renal Artery Diameter Is a Stronger Predictor of Contrast-Induced Nephropathy than Chronic Kidney Disease in Patients with High Cardiovascular Risk. Nephron Extra, 2011, 1, 38-44.	1.1	4
430	Response to Letter Regarding Article, â€œPharmacodynamic Effects of Different Aspirin Dosing Regimens in Type 2 Diabetes Mellitus Patients With Coronary Artery Diseaseâ€• Circulation: Cardiovascular Interventions, 2011, 4, .	1.4	0
431	Impact of Drug-Eluting Stents and Diabetes Mellitus in Patients With Coronary Bifurcation Lesions: A Survey From the Italian Society of Invasive Cardiology. Circulation: Cardiovascular Interventions, 2011, 4, 72-79.	1.4	6
432	Quality-of-life in elderly patients one year after transcatheter aortic valve implantation for severe aortic stenosis. EuroIntervention, 2011, 7, 573-579.	1.4	48

#	Article	IF	Citations
433	Properties and Clinical Development of a Novel Coating Technology: The poly[bis(trifluoroethoxy)phosphazene]. Recent Patents on Drug Delivery and Formulation, 2010, 4, 18-22.	2.1	10
434	Sirolimus versus paclitaxel-eluting stents in small coronary vessels: long-term outcomes from a single-center registry. Journal of Cardiovascular Medicine, 2010, 11, 365-368.	0.6	7
435	Rapid Evaluation of Vessel HEaling After AngiopLasty (REVEAL) trial: rationale, objectives and design. Journal of Cardiovascular Medicine, 2010, 11, 53-58.	0.6	5
436	ClearWayRX System to reduce intracoronary thrombus in patients with acute coronary syndromes according to Optical Coherence Tomography after Abciximab Intracoronary Local infusion trial (COCTAIL): study rationale and design. Journal of Cardiovascular Medicine, 2010, 11, 130-136.	0.6	11
437	Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y₁₂receptor antagonist. Expert Review of Cardiovascular Therapy, 2010, 8, 151-158.	0.6	76
438	Management of implant failure during transcatheter aortic valve implantation. Catheterization and Cardiovascular Interventions, 2010, 76, 440-449.	0.7	54
439	Plaque Distribution Patterns in Distal Left Main Coronary Artery to Predict Outcomes After Stent Implantation. JACC: Cardiovascular Interventions, 2010, 3, 624-631.	1.1	33
440	Local Delivery Versus Intracoronary Infusion of Abciximab in Patients With Acute Coronary Syndromes. JACC: Cardiovascular Interventions, 2010, 3, 928-934.	1.1	73
441	A Novel 3â€Ð Reconstruction System for the Assessment of Bifurcation Lesions Treated by the Miniâ€Crush Technique. Journal of Interventional Cardiology, 2010, 23, 46-53.	0.5	15
442	Prognostic Value of Exercise Myocardial Scintigraphy in Patients with Coronary Chronic Total Occlusions. Journal of Interventional Cardiology, 2010, 23, 139-148.	0.5	29
443	Impact of race and gender on antithrombotic therapy. Thrombosis and Haemostasis, 2010, 104, 471-484.	1.8	68
444	Pharmacodynamic Effects of Concomitant Versus Staggered Clopidogrel and Omeprazole Intake. Circulation: Cardiovascular Interventions, 2010, 3, 436-441.	1.4	58
445	Platelet thrombin receptor antagonism and atherothrombosis. European Heart Journal, 2010, 31, 17-28.	1.0	214
446	TAVI as a threat to surgical practice: "much ado about nothing" or "the quiet before the storm"?. Heart, 2010, 96, 1609-1610.	1.2	6
447	Transcatheter aortic valve implantation: what has been done and what is going to be done. Future Cardiology, 2010, 6, 83-95.	0.5	8
448	Percutaneous mitral valve repair with the MitraClip system: acute results from a real world setting. European Heart Journal, 2010, 31, 1382-1389.	1.0	230
449	Impact of Chronic Kidney Disease on Platelet Function Profiles in Diabetes Mellitus Patients With Coronary Artery Disease Taking Dual Antiplatelet Therapy. Journal of the American College of Cardiology, 2010, 55, 1139-1146.	1.2	193
450	Antithrombotic Therapy in the Elderly. Journal of the American College of Cardiology, 2010, 56, 1683-1692.	1.2	121

#	Article	IF	Citations
451	Sirolimus- vs. paclitaxel-eluting stents in patients undergoing off-label percutaneous coronary intervention. International Journal of Cardiology, 2010, 145, 299-300.	0.8	0
452	EuroSCORE refines the predictive ability of SYNTAX score in patients undergoing left main percutaneous coronary intervention. American Heart Journal, 2010, 159, 103-109.	1.2	108
453	Intraoperative defibrillation threshold testing during implantable cardioverter-defibrillator insertion: Do we really need it?. American Heart Journal, 2010, 159, 98-102.	1.2	21
454	Response to: SYNTAX score and left main stenting: Do we need clinical variables to predict outcomes?. American Heart Journal, 2010, 159, e27.	1.2	0
455	Real-world outcome of coronary bifurcation lesions in the drug-eluting stent era: Results from the 4,314-patient Italian Society of Invasive Cardiology (SICI-GISE) Italian Multicenter Registry on Bifurcations (I-BIGIS). American Heart Journal, 2010, 160, 535-542.e1.	1.2	40
456	Long-term outcomes after drug-eluting stent for the treatment of ostial left anterior descending coronary artery lesions. American Heart Journal, 2010, 160, 973-978.	1.2	19
457	Clinical Development of Selective Anticoagulants: A State of the Art. Reviews on Recent Clinical Trials, 2010, 5, 85-93.	0.4	3
458	Impact of right coronary artery disease on mortality in patients undergoing percutaneous coronary intervention of unprotected left main coronary artery disease. EuroIntervention, 2010, 6, 454-460.	1.4	9
459	Diabetes mellitus: the scary killer haunting silently. EuroIntervention, 2010, 5, 879-881.	1.4	5
460	Balloon aortic valvuloplasty for severe aortic stenosis as a bridge to high-risk transcatheter aortic valve implantation. Journal of Invasive Cardiology, 2010, 22, 161-6.	0.4	40
461	Are drug-eluting stents superior to bare-metal stents in patients with unprotected non-bifurcational left main disease? Insights from a multicentre registry. European Heart Journal, 2009, 30, 1171-1179.	1.0	50
462	Evolution of stents: past, present and future. Expert Review of Cardiovascular Therapy, 2009, 7, 443-446.	0.6	8
463	Quality of life assessment after percutaneous aortic valve implantation. European Heart Journal, 2009, 30, 1790-1796.	1.0	84
464	Usefulness of the SYNTAX Score for Predicting Clinical Outcome After Percutaneous Coronary Intervention of Unprotected Left Main Coronary Artery Disease. Circulation: Cardiovascular Interventions, 2009, 2, 302-308.	1.4	196
465	Comparison of Drug-Eluting Stents and Bare-Metal Stents for the Treatment of Unprotected Left Main Coronary Artery Disease in Acute Coronary Syndromes. American Journal of Cardiology, 2009, 103, 187-193.	0.7	36
466	Optical Coherence Tomographic Results at Six-Month Follow-Up Evaluation of the CATANIA Coronary Stent System With NanoThin Polyzene-F Surface Modification (from the Assessment of The LAtest) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 1551-1555.	0.7	20
467	Early and mid-term clinical outcomes with the CATANIA coronary stent system vs. bare metal stents in patients with coronary artery disease. Cardiovascular Revascularization Medicine, 2009, 10, 216-220.	0.3	4
468	Real world safety and efficacy of the Janus tacrolimusâ€eluting stent: Longâ€term clinical outcome and angiographic findings from the tacrolimusâ€eluting stent (TEST) registry. Catheterization and Cardiovascular Interventions, 2009, 73, 243-248.	0.7	23

#	Article	IF	Citations
469	Longâ€term clinical benefit of drugâ€eluting stents over bareâ€metal stents in diabetic patients with de novo left main coronary artery disease: Results from a realâ€world multicenter registry. Catheterization and Cardiovascular Interventions, 2009, 73, 310-316.	0.7	5
470	Percutaneous closure of patent foramen ovale with a bioabsorbable occluder device. Catheterization and Cardiovascular Interventions, 2009, 74, 607-614.	0.7	22
471	A novel approach to define risk of stent thrombosis after percutaneous coronary intervention with drug-eluting stents: the DERIVATION score. Clinical Research in Cardiology, 2009, 98, 240-248.	1.5	12
472	Contemporary issues on clopidogrel therapy: a critical appraisal. Internal and Emergency Medicine, 2009, 4, 195-198.	1.0	2
473	Early Conduction Disorders Following Percutaneous Aortic Valve Replacement. PACE - Pacing and Clinical Electrophysiology, 2009, 32, S126-30.	0.5	71
474	Mini-Crush Versus T-Provisional Techniques in Bifurcation Lesions. JACC: Cardiovascular Interventions, 2009, 2, 185-194.	1.1	32
475	First-in-Man 1-Year Clinical Outcomes of the Catania Coronary Stent System With Nanothin Polyzene-F in De Novo Native Coronary Artery Lesions. JACC: Cardiovascular Interventions, 2009, 2, 197-204.	1.1	30
476	Usefulness of SYNTAX Score to Select Patients With Left Main Coronary Artery Disease to Be Treated With Coronary Artery Bypass Graft. JACC: Cardiovascular Interventions, 2009, 2, 731-738.	1.1	150
477	Transesophageal echocardiography and transcranial color Doppler: independent or complementary diagnostic tests for cardiologists in the detection of patent foramen ovale?. Journal of Cardiovascular Medicine, 2009, 10, 143-148.	0.6	13
478	Cost-effectiveness of the real-world use of drug-eluting stents at 9-month follow-up: results from the Sicilian DES Registry. Journal of Cardiovascular Medicine, 2009, 10, 322-329.	0.6	3
479	Transcranial color Doppler is essential to quantify right to left shunt severity. Journal of Cardiovascular Medicine, 2009, 10, 890.	0.6	1
480	Long-term follow-up after drug eluting stent implantation in left main trifurcations. EuroIntervention, 2009, 5, 432-437.	1.4	9
481	Comparison of optical coherence tomography and intravascular ultrasound for the assessment of in-stent tissue coverage after stent implantation. EuroIntervention, 2009, 5, 538-543.	1.4	54
482	Procedural success and 30-day clinical outcomes after percutaneous aortic valve replacement using current third-generation self-expanding CoreValve prosthesis. Journal of Invasive Cardiology, 2009, 21, 93-8.	0.4	34
483	Pursuing the goal to improve downstream myocardial tissue perfusion. European Heart Journal, 2008, 30, 750-751.	1.0	1
484	Early discharge in acute myocardial infarction after clinical and angiographic risk assessment. Journal of Cardiovascular Medicine, 2008, 9, 858-861.	0.6	5